Atossa Genetics (NASDAQ:ATOS) reports final results from its Phase 1 dose-escalation study of topical Endoxifen in 24 male subjects.
All objectives were successfully met. No clinically significant safety signals and adverse events were observed. Topical Endoxifen was well tolerated at each dose level and blood samples showed no measurable Endoxifen.
Phase 2 study using topical Endoxifen in women with mammographic breast density (MBD) is anticipated to be completed in Q2 2019.
Shares are up 41% premarket.
Previously: Atossa Genetics announces preliminary results from male Phase 1 study of topical endoxifen (Sept. 13, 2018)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.